Click Therapeutics, Inc. Honored by Goldman Sachs for Entrepreneurship

 David Benshoof Klein, CEO Among 100 Most Intriguing Entrepreneurs at 2019 Builders + Innovators Summit

NEW YORK–(BUSINESS WIRE)–Goldman Sachs (NYSE:GS) is recognizing Click Therapeutics, Inc.’s (“Click”) co-founder and CEO, David Benshoof Klein, as one of the 100 Most Intriguing Entrepreneurs of 2019 at its Builders + Innovators Summit in Santa Barbara, California.

Goldman Sachs selected Mr. Klein as one of 100 entrepreneurs from multiple industries to be honored at the three-day event. Mr. Klein is an investor and entrepreneur with over 18 years of life science industry experience, and has played key roles in founding, financing and operating numerous life science companies. In 2012, Mr. Klein co-founded Click Therapeutics, a leader in the development and commercialization of software as medical treatments, and conceived of the term Digital Therapeutics to reference this now burgeoning industry.

“In the past year, our diverse team of engineers, designers, data scientists, product managers, clinicians, scientists, privacy and regulatory experts have made rapid progress across a broad pipeline of novel digital therapeutics, helping to position the company as the clear market leader in software as first-line medical treatments,” said CEO David Benshoof Klein. “Patients and prescribers can have confidence in the work of our team as we put our software treatments through the same rigorous quality controls, clinical validation, and regulatory review as traditional medical devices and drugs. Further, our products leverage the latest in user experience design principles and data security methodology to put the needs of the patient at the center. We are excited to bring these novel, safe, effective and engaging therapies to those in need of new treatment options.”

“True innovation is built from a diversity of perspectives and experiences,” said David M. Solomon, Chief Executive Officer of Goldman Sachs. “Our Builders + Innovators Summit brings together a collective of impressive future leaders who are striving to drive meaningful change. For 150 years, Goldman Sachs has supported entrepreneurs as they launch and grow their businesses. That’s why we are pleased to recognize Mr. Klein as one of the most intriguing entrepreneurs of 2019.”

In addition to honoring 100 entrepreneurs, the summit consists of general sessions and clinics led by seasoned entrepreneurs, academics and business leaders as well as resident scholars.

About Click Therapeutics

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults. For more information, visit ClickTherapeutics.com.

Contacts

Company Contact
Sarah Jackson

Chief of Staff

[email protected]

Media Contact
Karen Sharma

[email protected]
781-235-3060